Edwards Executive Sells Entire Stock Option Holdings Worth $24 Million

Donald E. Bobo Jr., Edwards Lifesciences’ executive in charge of strategy and corporate development, exercised 22,680 stock options on April 2 and immediately sold the same number of shares in the open market. The shares fetched roughly $80 each, generating proceeds of about $1.82 million (approximately KRW 2.4 billion). After the transaction, he still holds direct equity valued at around KRW 2.4 billion, plus indirect holdings of about KRW 18 billion through his 401(k) plan and a trust. The sale was executed under a pre-established Rule 10b5-1 trading plan, as disclosed.

Recently, Edwards Lifesciences has received and maintained “Outperform” ratings from major brokerages such as Wolfe Research and Evercore ISI, with price targets set in the low $90 range. Benefiting from an analyst upgrade in early April and increased institutional buying, trading volume surged and the stock closed at about $81 on April 8, up roughly 1%.

Headquartered in Irvine, California, Edwards Lifesciences is a medical technology company specializing in artificial heart valves, catheter-based treatments for structural heart disease, and critical-care hemodynamic monitoring devices. Since spinning off from Baxter International in 2000, it has been regarded as a global leader in structural heart disease and is known for its strong institutional-investor base supported by a long-term growth narrative.